ALK and angioimmunoblastic T-cell lymphoma: As shown in Figure 3A, patients with ALK-ALCL had the longest median PFS (26.0 months), followed by PTCL-NOS (19.4 months), AITL (9.6 months), and EATL (3.2 months; P < 0.05).